Pipeline

Pipeline

R&D Outline	R&D stage
R&D Outline	Seed	Preclinical	GMP/GCTP production	Early clinical trial
GAIA-102（iv）Detail
Technology GAIA NK-like cell platform Cell Source PBMCs Target NSCLCs
GAIA-102（ip）Detail
Technology GAIA NK-like cell platform Cell Source PBMCs Target Gastric cancer, Pancreatic cancer
GAIA-102（iv + pretreatment）Detail
Technology GAIA NK-like cell platform Cell Source PBMCs Target Neuroblastoma, etc.
GAIA-121 - 125Detail
Technology GAIA NK-like cell platform GAAAP Cell Source PBMCs
GAIA-202Detail
Technology GAIA NK-like cell platform Cell Source ES/iPS
GAIA-251Detail
Technology GAIA NK-like cell platform Cell Source ES/iPS

R&D Outline
R&D Outline	GAIA-102（iv）Detail
Technology GAIA NK-like cell platform Cell Source PBMCs Target NSCLCs

R&D stage
Seed	Preclinical	GMP/GCTP production	Early clinical trial

R&D Outline
R&D Outline	GAIA-102（ip）Detail
Technology GAIA NK-like cell platform Cell Source PBMCs Target Gastric cancer, Pancreatic cancer

R&D stage
Seed	Preclinical	GMP/GCTP production	Early clinical trial

R&D Outline
R&D Outline	GAIA-102（iv + pretreatment）Detail
Technology GAIA NK-like cell platform Cell Source PBMCs Target Neuroblastoma, etc.

R&D stage
Seed	Preclinical	GMP/GCTP production	Early clinical trial

R&D Outline
R&D Outline	GAIA-121 - 125Detail
Technology GAIA NK-like cell platformGAAAP Cell Source PBMCs

R&D stage
Seed	Preclinical	GMP/GCTP production	Early clinical trial

R&D Outline
R&D Outline	GAIA-202Detail
Technology GAIA NK-like cell platform Cell Source ES/iPS

R&D stage
Seed	Preclinical	GMP/GCTP production	Early clinical trial

R&D Outline
R&D Outline	GAIA-251Detail
Technology GAIA NK-like cell platform Cell Source ES/iPS

R&D stage
Seed	Preclinical	GMP/GCTP production	Early clinical trial

GAIA-102（iv）

GAIA NK-like cell platform

Description :: No modification

Cell source :: PBMCs

Gene transfer :: No

Target	Administration route	R&D stage								Partners
Target	Administration route	Region	Seed	Preclinical	GMP/GCTP production	Early clinical trial	Conditioned approval	Late clinical trial	On the market	Partners
NSCLCs	intravenous	JAPAN Others

Target		NSCLCs
Administration route		intravenous
R&D stage	Region	JAPAN Others
	Seed
	Preclinical
	GMP/GCTP production
	Early clinical trial
	Conditioned approval
	Late clinical trial
	On the market
Partners

GAIA-102（ip）

GAIA NK-like cell platform

Description :: No modification

Cell source :: PBMCs

Gene transfer :: No

Target	Administration route	R&D stage								Partners
Target	Administration route	Region	Seed	Preclinical	GMP/GCTP production	Early clinical trial	Conditioned approval	Late clinical trial	On the market	Partners
Gastric cancer, Pancreatic cancer	intravenous/ intraperitoneal	JAPAN Others

Target		Gastric cancer
Administration route		intravenous/ intraperitoneal
R&D stage	Region	JAPAN Others
	Seed
	Preclinical
	GMP/GCTP production
	Early clinical trial
	Conditioned approval
	Late clinical trial
	On the market
Partners

GAIA-102（iv + pretreatment）

GAIA NK-like cell platform

Description :: No modification

Cell source :: PBMCs

Gene transfer :: No

Target	Administration route	R&D stage								Partners
Target	Administration route	Region	Seed	Preclinical	GMP/GCTP production	Early clinical trial	Conditioned approval	Late clinical trial	On the market	Partners
Neuroblastoma, etc.	intravenous	JAPAN Others

Target		Neuroblastoma, etc.
Administration route		intravenous/ intraperitoneal
R&D stage	Region	JAPAN Others
	Seed
	Preclinical
	GMP/GCTP production
	Early clinical trial
	Conditioned approval
	Late clinical trial
	On the market
Partners

GAIA-121 - 125

GAIA NK-like cell platformGAAAP

Description :: Ab-armed

Cell source :: PBMCs

Gene transfer :: No

Target	Administration route	R&D stage								Partners
Target	Administration route	Region	Seed	Preclinical	GMP/GCTP production	Early clinical trial	Conditioned approval	Late clinical trial	On the market	Partners
A + tumors	intravenous	JAPAN Others
B + tumors	intravenous	JAPAN Others
C + tumors	intravenous	JAPAN Others
D + tumors	intravenous	JAPAN Others
E + tumors	intravenous	JAPAN Others

Target		A + tumors	B + tumors	C + tumors	D + tumors	E + tumors
Administration route		intravenous	intravenous	intravenous	intravenous	intravenous
R&D stage	Region	JAPAN Others	JAPAN Others	JAPAN Others	JAPAN Others	JAPAN Others
	Seed
	Preclinical
	GMP/GCTP production
	Early clinical trial
	Conditioned approval
	Late clinical trial
	On the market
Partners

GAIA-202

GAIA NK-like cell platform

Description :: No modification

Cell source :: ESCs/iPSCs

Gene transfer :: No

Target	Administration route	R&D stage								Partners
Target	Administration route	Region	Seed	Preclinical	GMP/GCTP production	Early clinical trial	Conditioned approval	Late clinical trial	On the market	Partners
to be determined	intravenous	JAPAN Others

Target		to be determined
Administration route		intravenous
R&D stage	Region	JAPAN Others
	Seed
	Preclinical
	GMP/GCTP production
	Early clinical trial
	Conditioned approval
	Late clinical trial
	On the market
Partners

GAIA-251

GAIA NK-like cell platform

Description :: CAR-modified

Cell source :: ESCs/iPSCs

Gene transfer :: Yes (CAR)

Target	Administration route	R&D stage								Partners
Target	Administration route	Region	Seed	Preclinical	GMP/GCTP production	Early clinical trial	Conditioned approval	Late clinical trial	On the market	Partners
to be determined	intravenous	JAPAN Others

Target		to be determined
Administration route		intravenous
R&D stage	Region	JAPAN Others
	Seed
	Preclinical
	GMP/GCTP production
	Early clinical trial
	Conditioned approval
	Late clinical trial
	On the market
Partners

GMP :: Good Manufacturing Practice

GCTP :: Good Cell and Tissue Practice

Ab :: Antibody

NSCLC :: Non-small cell lung cancer

CAR :: Chimeric antigen receptor

PBMC :: Peripheral blood mononuclear cell

ESC :: Embryonic stem cell

iPSC :: Induced pluripotent stem cell

GAIA BioMedicine Pipeline